NCT05312970 - Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions

Varicose Veins

Interventions

DRUG

Varithena®

Varithena® (polidocanol injectable foam) 1%

DEVICE

FDA-approved Endothermal Ablation (ETA) systems

FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.

Trial Locations (9)

Columbia University Medical Center, New York

Stony Brook University Hospital, Stony Brook

Medstar Georgetown University Hospital, Washington D.C.

Cardiovascular Institute of the South, Houma

UT Physicians Cardiothoracic and Vascular Surgery, Houston

Lake Washington Vascular, Bellevue

Vascular Care Connecticut, Darien

Vein Healthcare Center, South Portland

Englewood Hospital and Medical Center, Englewood